---
figid: PMC4314372__nihms-652713-f0001
figtitle: Biology of Castrate Resistant Prostate Cancer
organisms:
- Homo sapiens
- Mus musculus
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
- Danio rerio
pmcid: PMC4314372
filename: nihms-652713-f0001.jpg
figlink: /pmc/articles/PMC4314372/figure/F1/
number: F1
caption: '(A) TGF-β pathway is stimulated via TGF-β induced receptor complex activation,
  leading to phosphorylation of SMAD2/3 and subsequently form a trimer with SMAD4
  and translocate to the nucleus and associate with other transcription factors to
  transcribe SOX4 which activates EZH2 expression leading to EMT. (B) Prostate cancer
  cells depend on the androgen receptor (AR) pathway and steroid hormones for continued
  oncogenic growth. This can occur by way of AR over expression or by AR gene amplification.
  Mutations in AR allow binding and activation of AR by other steroidal hormones.
  Wnt pathway genes are frequently mutated in CRPC and are transcriptional targets
  of AR. (C) Activation of the PI3K-AKT-mTOR pathway is extremely common in CRPC.
  Activated growth factor receptor tyrosine kinases (e.g. EGFR and IGF-1R) leads to
  activated PDK1, which in turn activates AKT. AKT separately phosphorylates and activates
  mTOR which promotes cell cycle progression, protein synthesis and decreased apoptosis.
  AKT can interact with AR in an androgen independent manner. (D) Activation of Receptor
  Tyrosine Kinase (RTK) pathway (PDGFR, HGFR/c-MET, etc) leads to proliferation through
  RAS-MAPK. Combined with loss of PTEN, overactive RAS-MAPK can induce EMT. (E) Intratumoral
  synthesis of steroidal hormones from cholesterol via upregulation of the cytochrome
  P450 gene CYP17A1. (F) Loss of the PTEN Tumor Suppressor promotes aberrant PI3K-AKT-mTOR
  signaling. (G) Aberrant Y534 phosphorylation by Src increases AR sensitivity to
  androgens. (H) Epigenetic Pathways: Hypermethylation of CpG islands in gene promoters
  inhibits expression of tumor suppressor genes or miRNAs targeting AR.'
papertitle: The Biology of Castrate Resistant Prostate Cancer.
reftext: Fei Lian, et al. Curr Probl Cancer. ;39(1):17-28.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8902058
figid_alias: PMC4314372__F1
figtype: Figure
redirect_from: /figures/PMC4314372__F1
ndex: c257752f-df15-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4314372__nihms-652713-f0001.html
  '@type': Dataset
  description: '(A) TGF-β pathway is stimulated via TGF-β induced receptor complex
    activation, leading to phosphorylation of SMAD2/3 and subsequently form a trimer
    with SMAD4 and translocate to the nucleus and associate with other transcription
    factors to transcribe SOX4 which activates EZH2 expression leading to EMT. (B)
    Prostate cancer cells depend on the androgen receptor (AR) pathway and steroid
    hormones for continued oncogenic growth. This can occur by way of AR over expression
    or by AR gene amplification. Mutations in AR allow binding and activation of AR
    by other steroidal hormones. Wnt pathway genes are frequently mutated in CRPC
    and are transcriptional targets of AR. (C) Activation of the PI3K-AKT-mTOR pathway
    is extremely common in CRPC. Activated growth factor receptor tyrosine kinases
    (e.g. EGFR and IGF-1R) leads to activated PDK1, which in turn activates AKT. AKT
    separately phosphorylates and activates mTOR which promotes cell cycle progression,
    protein synthesis and decreased apoptosis. AKT can interact with AR in an androgen
    independent manner. (D) Activation of Receptor Tyrosine Kinase (RTK) pathway (PDGFR,
    HGFR/c-MET, etc) leads to proliferation through RAS-MAPK. Combined with loss of
    PTEN, overactive RAS-MAPK can induce EMT. (E) Intratumoral synthesis of steroidal
    hormones from cholesterol via upregulation of the cytochrome P450 gene CYP17A1.
    (F) Loss of the PTEN Tumor Suppressor promotes aberrant PI3K-AKT-mTOR signaling.
    (G) Aberrant Y534 phosphorylation by Src increases AR sensitivity to androgens.
    (H) Epigenetic Pathways: Hypermethylation of CpG islands in gene promoters inhibits
    expression of tumor suppressor genes or miRNAs targeting AR.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - pk
  - ras
  - Hras
  - Kras
  - Rem1
  - Tgfb1
  - Ltbp1
  - Cyp17a1
  - Pik3r1
  - Pten
  - Ar
  - Smad2
  - Smad3
  - Akt1
  - Zhx2
  - Src
  - Mdk
  - Smad4
  - Mtor
  - Ephb2
  - Mapk1
  - Myc
  - Nol3
  - Ctnnb1
  - Sox9
  - Alpha-re
  - Mir34a
  - Twsg1
  - Ezh2
  - Itk
  - Slc22a3
  - Erg
  - Sox4
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - KRAS
  - HRAS
  - NRAS
  - TGFB1
  - TGFB2
  - TGFB3
  - CYP17A1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PTEN
  - AR
  - SMAD2
  - SMAD3
  - AKT1
  - AKT2
  - AKT3
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - SRC
  - FGR
  - FYN
  - YES1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - SMAD4
  - MTOR
  - EPHB2
  - E2F1
  - E2F2
  - E2F3
  - E2F4
  - E2F5
  - E2F6
  - E2F7
  - E2F8
  - MYC
  - CTNNB1
  - SOX9
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - MIR34A
  - TWSG1
  - RASEF
  - EZH2
  - ITK
  - SLC22A3
  - ERG
  - SOX4
  - MKP-4
  - p38b
  - rl
  - Ras64B
  - Ras85D
  - dpp
  - gbb
  - put
  - mav
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - ar
  - Smox
  - Akt
  - Raf
  - Src42A
  - Csk
  - Src64B
  - Dsor1
  - Mtk
  - CycE
  - cyc
  - Med
  - Tor
  - Erk7
  - ebi
  - E2f2
  - E2f1
  - arm
  - Sox100B
  - Wnt5
  - Wnt4
  - wg
  - Wnt2
  - tsg
  - E(z)
  - sei
  - pak2a
  - itpka
  - kita
  - ngfra
  - rab1ab
  - cyp17a1
  - ptenb
  - smad2
  - smad3a
  - src
  - smad4a
  - smad4b
  - mtor
  - myca
  - mycbp2
  - ctnnb1
  - mir34a
  - twsg1a
  - ezh2
  - erg
  - kcnh6a
  - sox4a
  - Androgen
  - Tyrosine
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
